skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 21 - 40 of 12,400  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
previous page 1 Results 2 3 4 5 next page
Refined by: subject: Clinical Trials remove subject: Research & Development remove
Result Number Material Type Add to My Shelf Action Record Details and Options
21
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials
Material Type:
Article 		Add to My Research

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials

The Lancet (British edition), 2018-02, Vol.391 (10120), p.563-571 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Feb 10, 2018 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)33106-9 ;PMID: 29217375

Full text available

Citations Cited by
22
The target landscape of clinical kinase drugs
The target landscape of clinical kinase drugs
Material Type:
Article 		Add to My Research

The target landscape of clinical kinase drugs

Science (American Association for the Advancement of Science), 2017-12, Vol.358 (6367), p.1148-1148 [Peer Reviewed Journal]

Copyright © 2017 by the American Association for the Advancement of Science ;Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. ;Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works ;ISSN: 0036-8075 ;EISSN: 1095-9203 ;DOI: 10.1126/science.aan4368 ;PMID: 29191878

Digital Resources/Online E-Resources

Citations Cited by
23
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
Material Type:
Article 		Add to My Research

Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox

The New England journal of medicine, 2019-11, Vol.381 (20), p.1897-1908 [Peer Reviewed Journal]

Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1817307 ;PMID: 31722150

Full text available

Citations Cited by
24
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review
Material Type:
Article 		Add to My Research

Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review

Journal of the American College of Cardiology, 2020-02, Vol.75 (4), p.435-447 [Peer Reviewed Journal]

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;2020. American College of Cardiology Foundation ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2019.11.036 ;PMID: 32000956

Full text available

Citations Cited by
25
Trends in the global immuno-oncology landscape
Trends in the global immuno-oncology landscape
Material Type:
Article 		Add to My Research

Trends in the global immuno-oncology landscape

Nature reviews. Drug discovery, 2018-11, Vol.17 (11), p.783-784 [Peer Reviewed Journal]

COPYRIGHT 2018 Nature Publishing Group ;Copyright Nature Publishing Group Nov 2018 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2018.167 ;PMID: 30337722

Full text available

Citations Cited by
26
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial
Material Type:
Article 		Add to My Research

Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial

The Lancet (British edition), 2017-10, Vol.390 (10104), p.1758-1768 [Peer Reviewed Journal]

2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Oct 14, 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)31465-4 ;PMID: 28803710

Full text available

Citations Cited by
27
Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks
Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks
Material Type:
Article 		Add to My Research

Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks

The New England journal of medicine, 2020-04, Vol.382 (14), p.1366-1369 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMsb1905390 ;PMID: 32242365

Full text available

Citations Cited by
28
Bridging the Gap at Warp Speed — Delivering Options for Preventing and Treating Covid-19
Bridging the Gap at Warp Speed — Delivering Options for Preventing and Treating Covid-19
Material Type:
Article 		Add to My Research

Bridging the Gap at Warp Speed — Delivering Options for Preventing and Treating Covid-19

The New England journal of medicine, 2020-11, Vol.383 (20), p.1899-1901 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMp2028535 ;PMID: 32931679

Full text available

Citations Cited by
29
Application of Bayesian approaches in drug development: starting a virtuous cycle
Application of Bayesian approaches in drug development: starting a virtuous cycle
Material Type:
Article 		Add to My Research

Application of Bayesian approaches in drug development: starting a virtuous cycle

Nature reviews. Drug discovery, 2023-03, Vol.22 (3), p.235-250 [Peer Reviewed Journal]

2023. Springer Nature Limited. ;Springer Nature Limited 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;Springer Nature Limited 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/s41573-023-00638-0 ;PMID: 36792750

Full text available

Citations Cited by
30
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis
Material Type:
Article 		Add to My Research

Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis

The Lancet (British edition), 2019-11, Vol.394 (10211), p.1816-1826 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(19)32317-7 ;PMID: 31668726

Full text available

Citations Cited by
31
Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil
Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil
Material Type:
Article 		Add to My Research

Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil

Nature communications, 2017-08, Vol.8 (1), p.190-10, Article 190 [Peer Reviewed Journal]

2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Distributed under a Creative Commons Attribution 4.0 International License ;The Author(s) 2017 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-017-00176-5 ;PMID: 28775348

Full text available

Citations Cited by
32
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
Material Type:
Article 		Add to My Research

Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

Molecular therapy, 2017-10, Vol.25 (10), p.2245-2253 [Peer Reviewed Journal]

2017 ;Published by Elsevier Inc. ;Copyright Elsevier Limited Oct 4, 2017 ;ISSN: 1525-0016 ;EISSN: 1525-0024 ;DOI: 10.1016/j.ymthe.2017.07.004 ;PMID: 28803861

Full text available

Citations Cited by
33
Recommendations for mechanical ventilation of critically ill children from the Paediatric Mechanical Ventilation Consensus Conference (PEMVECC)
Recommendations for mechanical ventilation of critically ill children from the Paediatric Mechanical Ventilation Consensus Conference (PEMVECC)
Material Type:
Article 		Add to My Research

Recommendations for mechanical ventilation of critically ill children from the Paediatric Mechanical Ventilation Consensus Conference (PEMVECC)

Intensive care medicine, 2017-12, Vol.43 (12), p.1764-1780 [Peer Reviewed Journal]

The Author(s) 2017 ;COPYRIGHT 2017 Springer ;Intensive Care Medicine is a copyright of Springer, (2017). All Rights Reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0342-4642 ;EISSN: 1432-1238 ;DOI: 10.1007/s00134-017-4920-z ;PMID: 28936698

Full text available

Citations Cited by
34
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials
Material Type:
Article 		Add to My Research

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials

PLoS medicine, 2010-03, Vol.7 (3), p.e1000251-e1000251 [Peer Reviewed Journal]

COPYRIGHT 2010 Public Library of Science ;COPYRIGHT 2010 Public Library of Science ;Schulz et al. 2010 ;2010 Schulz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Schulz KF, Altman DG, Moher D, for the CONSORT Group (2010) CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLoS Med 7(3): e1000251. doi:10.1371/journal.pmed.1000251 ;ISSN: 1549-1676 ;ISSN: 1549-1277 ;EISSN: 1549-1676 ;DOI: 10.1371/journal.pmed.1000251 ;PMID: 20352064

Full text available

Citations Cited by
35
Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies
Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies
Material Type:
Article 		Add to My Research

Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies

PloS one, 2013-08, Vol.8 (8), p.e71966-e71966 [Peer Reviewed Journal]

COPYRIGHT 2013 Public Library of Science ;COPYRIGHT 2013 Public Library of Science ;2013 Thomas J. Hwang. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2013 Thomas J 2013 Thomas J ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0071966 ;PMID: 23951273

Full text available

Citations Cited by
36
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial
Material Type:
Article 		Add to My Research

Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial

The Lancet (British edition), 2019-03, Vol.393 (10176), p.1128-1137 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)32003-8 ;PMID: 30853151

Full text available

Citations Cited by
37
Completeness of Follow-Up Determines Validity of Study Findings: Results of a Prospective Repeated Measures Cohort Study
Completeness of Follow-Up Determines Validity of Study Findings: Results of a Prospective Repeated Measures Cohort Study
Material Type:
Article 		Add to My Research

Completeness of Follow-Up Determines Validity of Study Findings: Results of a Prospective Repeated Measures Cohort Study

PloS one, 2015-10, Vol.10 (10), p.e0140817-e0140817 [Peer Reviewed Journal]

COPYRIGHT 2015 Public Library of Science ;COPYRIGHT 2015 Public Library of Science ;2015 von Allmen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2015 von Allmen et al 2015 von Allmen et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0140817 ;PMID: 26469346

Full text available

Citations Cited by
38
An Updated Review on Efficiency of Penthorum chinense Pursh in Traditional Uses, Toxicology, and Clinical Trials
An Updated Review on Efficiency of Penthorum chinense Pursh in Traditional Uses, Toxicology, and Clinical Trials
Material Type:
Article 		Add to My Research

An Updated Review on Efficiency of Penthorum chinense Pursh in Traditional Uses, Toxicology, and Clinical Trials

BioMed research international, 2023-02, Vol.2023, p.4254051-11 [Peer Reviewed Journal]

Copyright © 2023 Fazul Nabi et al. ;COPYRIGHT 2023 Hindawi Limited ;Copyright © 2023 Fazul Nabi et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0 ;Copyright © 2023 Fazul Nabi et al. 2023 ;ISSN: 2314-6133 ;EISSN: 2314-6141 ;DOI: 10.1155/2023/4254051 ;PMID: 36852294

Full text available

Citations Cited by
39
Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications
Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications
Material Type:
Article 		Add to My Research

Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications

Cells (Basel, Switzerland), 2019-04, Vol.8 (5), p.403 [Peer Reviewed Journal]

2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 by the authors. 2019 ;ISSN: 2073-4409 ;EISSN: 2073-4409 ;DOI: 10.3390/cells8050403 ;PMID: 31052294

Full text available

Citations Cited by
40
POS1535 EARLY IMPROVEMENT IN 3VAS/4VAS PREDICTS REDUCED RATES OF RADIOGRAPHIC CHANGE IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT
POS1535 EARLY IMPROVEMENT IN 3VAS/4VAS PREDICTS REDUCED RATES OF RADIOGRAPHIC CHANGE IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT
Material Type:
Article 		Add to My Research

POS1535 EARLY IMPROVEMENT IN 3VAS/4VAS PREDICTS REDUCED RATES OF RADIOGRAPHIC CHANGE IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1131-1132 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1690

Full text available

Citations Cited by

Results 21 - 40 of 12,400  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
previous page 1 Results 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
  1. Before 1992  (10)
  2. 1992 To 1999  (77)
  3. 2000 To 2007  (493)
  4. 2008 To 2016  (2,424)
  5. After 2016  (9,397)
  6. More options open sub menu

Subject 

  1. R&d  (12,395)
  2. Medical Research  (12,126)
  3. Pharmaceutical Industry  (3,244)
  4. Patients  (3,178)
  5. Cancer Therapies  (3,087)
  6. Oncology  (2,895)
  7. Biotechnology Industry  (2,712)
  8. Tumors  (2,682)
  9. Net Losses  (2,670)
  10. Collaboration  (2,659)
  11. Cancer  (2,540)
  12. Coronaviruses  (2,184)
  13. Covid-19  (2,158)
  14. Drug Dosages  (1,850)
  15. Financial Performance  (1,850)
  16. Immunotherapy  (1,810)
  17. Stockholders  (1,583)
  18. Fda Approval  (1,579)
  19. More options open sub menu

Language 

  1. English  (12,397)
  2. Japanese  (91)
  3. Urdu  (17)
  4. Chinese  (2)
  5. Norwegian  (2)
  6. French  (1)
  7. German  (1)
  8. Spanish  (1)
  9. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait